Lisa Lundgren
Fred Hutchinson Cancer Research Center
9 Papers
5 Citations
Lisa Lundgren is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Pembrolizumab & Merkel cell carcinoma. The author has an hindex of 7, co-authored 9 publications.
Chat about Author
Papers
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul Nghiem,Shailender Bhatia,Evan J. Lipson,Ragini R. Kudchadkar,Natalie J. Miller,Lakshmanan Annamalai,Sneha Berry,Elliot Chartash,Adil Daud,Steven P. Fling,Philip Friedlander,Harriet M. Kluger,Holbrook E Kohrt,Lisa Lundgren,Kim Margolin,Alan Mitchell,Thomas Olencki,Drew M. Pardoll,Sunil Reddy,E. Shantha,William H. Sharfman,Elad Sharon,Lynn Shemanski,Michi M. Shinohara,Joel C. Sunshine,Janis M. Taube,John A. Thompson,John A. Thompson,Steven M. Townson,Jennifer H. Yearley,Suzanne L. Topalian,Martin A. Cheever,Martin A. Cheever +32 more
TL;DR: First-line therapy with pembrolizumab in patients with advanced Merkel-cell carcinoma was associated with an objective response rate of 56% and effectiveness was correlated with tumor viral status, as assessed by serologic and immunohistochemical testing.
1.1K
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study.
Thomas S. Uldrick,Thomas S. Uldrick,Priscila H. Goncalves,Priscila H. Goncalves,Maher Abdul-Hay,Alisa J Claeys,Brinda Emu,Marc S. Ernstoff,Steven P. Fling,Lawrence Fong,Judith C Kaiser,Andreanne M. Lacroix,Steve Young Lee,Lisa Lundgren,Kathryn Lurain,Christopher H Parsons,Christopher H Parsons,Sharavi Peeramsetti,Ramya Ramaswami,Elad Sharon,Mario Sznol,Chia-Ching Jackie Wang,Robert Yarchoan,Martin A. Cheever +23 more
TL;DR: Pembrolizumab has acceptable safety in patients with cancer, HIV treated with ART, and a CD4+ T-cell count of greater than 100 cells/μL but may be associated with KSHV-associated B-cell lymphoproliferation but is appropriate for US Food and Drug Administration-approved indications and clinical trials in this population.
Tuberculosis following PD-1 blockade for cancer immunotherapy
Daniel L. Barber,Shunsuke Sakai,Ragini R. Kudchadkar,Steven P. Fling,Tracey A. Day,Julie Vergara,David Ashkin,Jonathan Cheng,Lisa Lundgren,Vanessa Raabe,Colleen S. Kraft,Jorge Nieva,Martin A. Cheever,Paul Nghiem,Elad Sharon +14 more
TL;DR: A patient who succumbed to disseminated tuberculosis after PD-1 blockade for treatment of nasopharyngeal carcinoma is described and Mtb-specific immune responses in a patient with Merkel cell carcinoma who developed checkpoint blockade–associated tuberculosis and was successfully treated for the infection are examined.
170
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets
Nina Bhardwaj,Philip Friedlander,Anna C. Pavlick,Marc S. Ernstoff,Brian R. Gastman,Brent A. Hanks,Brendan D. Curti,Mark R. Albertini,Jason J. Luke,Ana Belen Blazquez,Sreekumar Balan,Davide Bedognetti,Joseph M. Beechem,Andrea Crocker,Leonard A D'Amico,Patrick Danaher,Thomas A. Davis,Thomas Hawthorne,Bruce W. Hess,Tibor Keler,Lisa Lundgren,Chihiro Morishima,Nirasha Ramchurren,Darawan Rinchai,Andres M. Salazar,Bob Salim,Elad Sharon,Laura Vitale,Ena Wang,Sarah Warren,Michael J. Yellin,Mary L. Disis,Martin A. Cheever,Steven P. Fling +33 more
- 16 Nov 2020
TL;DR: In vivo effects of Flt3L on innate immune cells in the setting of vaccination, leading to an immunogenic vaccine regimen, is revealed and gene signatures associated with CDX-301 induction of an early, durable immune response are revealed.
88
Phase I study of pembrolizumab in people with HIV and cancer.
Thomas S. Uldrick,Priscila H. Goncalves,Mohammad Maher Abdul Hay,Alisa J Claeys,Brinda Emu,Marc S. Ernstoff,Lawrence Fong,Judith C Kaiser,Holbrook E Kohrt,Andreanne M. Lacroix,Steve Young Lee,Lisa Lundgren,Kathryn Lurain,Chris Parsons,Sharavi Peeramsetti,Ramya Ramaswami,Elad Sharon,Chia-Ching Jackie Wang,Robert Yarchoan,Martin A. Cheever +19 more
TL;DR: People with HIV have been excluded from immuno-oncology studies and pembrolizumab (pembro) was evaluated in studies evaluating anti- PD-1/PD-L1 therapies for cancers.
3